Search research articles
Contact Us
Filters
Showing results (221-230 of 289) with videos related to
Page
of 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Correction: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 15, 2022
Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2021
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 10, 2014
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors
Toshio Shimizu, Patricia M LoRusso, Kyri P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology
|
December 4, 2013
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
Anthony W Tolcher, Wendi V Rodrigueza, Drew W Rasco, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 22, 2020
Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer
Shir Schlosser, Rachel Rabinovitch, Zina Shatz, et al.
Biological Trace Element Research
|
December 20, 2012
Comparison of tissue metal concentrations in Zucker lean, Zucker obese, and Zucker diabetic fatty rats and the effects of chromium supplementation on tissue metal concentrations
Halina Staniek, Nicholas R Rhodes, Kristin R Di Bona, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 26, 2014
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
A W Tolcher, J C Bendell, K P Papadopoulos, et al.
Journal of Clinical Medicine
|
April 30, 2021
Prognostic Implication of Non-Obstructive Coronary Lesions: A New Classification in Different Settings
Jorge Rodríguez-Capitán, Andrés Sánchez-Pérez, Sara Ballesteros-Pradas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors
Amita Patnaik, Glen J Weiss, John E Leonard, et al.
Page
of 29
Search research articles
Search
Showing results (221-230 of 289) with videos related to
Sort By:
Page
of 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Correction: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 15, 2022
Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2021
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 10, 2014
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors
Toshio Shimizu, Patricia M LoRusso, Kyri P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology
|
December 4, 2013
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
Anthony W Tolcher, Wendi V Rodrigueza, Drew W Rasco, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 22, 2020
Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer
Shir Schlosser, Rachel Rabinovitch, Zina Shatz, et al.
Biological Trace Element Research
|
December 20, 2012
Comparison of tissue metal concentrations in Zucker lean, Zucker obese, and Zucker diabetic fatty rats and the effects of chromium supplementation on tissue metal concentrations
Halina Staniek, Nicholas R Rhodes, Kristin R Di Bona, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 26, 2014
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
A W Tolcher, J C Bendell, K P Papadopoulos, et al.
Journal of Clinical Medicine
|
April 30, 2021
Prognostic Implication of Non-Obstructive Coronary Lesions: A New Classification in Different Settings
Jorge Rodríguez-Capitán, Andrés Sánchez-Pérez, Sara Ballesteros-Pradas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors
Amita Patnaik, Glen J Weiss, John E Leonard, et al.
Page
of 29